Sialorrhea – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Sialorrhea Market Outlook

Thelansis’s “Sialorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sialorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sialorrhea Overview

Sialorrhea, also termed ptyalis or drooling, is an incapacitating phenomenon characterized by an excess accumulation of saliva in the oral cavity extending beyond the labial boundary. While drooling is common in typically developing infants, its prevalence diminishes between 15 to 36 months of age with the establishment of salivary control. Post the age of 4; this condition is regarded as abnormal. Pathological sialorrhea may arise as an isolated event due to heightened salivary secretion or may manifest concomitantly with various neurological conditions like amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), cerebral palsy (CP), or as an adverse effect of medications. In the pediatric population, CP is the leading cause of sialorrhea, persisting in 10%–38% of affected individuals. Conversely, PD is the predominant etiological factor in adults, accounting for sialorrhea in 70%–80% of PD patients. Notably, using clozapine in schizophrenic patients results in hypersalivation in 30%–80% of cases. Irrespective of the causative factor, drooling gives rise to clinical and functional complications, including impaired social functioning due to feelings of embarrassment and isolation, the potential for aspiration, skin integrity compromise, unpleasant odor, and susceptibility to infections. The principal salivary glands, encompassing the parotid, submandibular, and sublingual glands, play a vital role in the human body. Among these, the parotid gland is the largest. Saliva, secreted by these glands, is critical in lubrication, digestion, immune function, and overall homeostasis. In the unstimulated state, the submandibular and sublingual glands contribute 70% of total saliva production. Sialorrhea may emanate from augmented salivary generation due to idiopathic or drug-induced factors or mechanisms impeding the effective clearance of saliva from the oral cavity. Neurological disorders are often linked to sialorrhea, primarily stemming from compromised swallowing due to impaired neuromuscular coordination. This intricate coordination involves the harmonious interplay of structures encompassing the oral cavity, pharynx, larynx, and esophagus. In pediatric neurologic disorders, drooling appears to be more attributed to inefficiencies in tongue and bulbar control rather than an escalation in salivary secretion. Conservative therapeutic approaches entail modifications in dietary patterns or behaviors, oral-motor exercises, utilization of intra-oral devices like palatal training apparatuses, and medical interventions such as pharmacotherapy or botulinum toxin injections. Behavior modification strategies have been recommended for an extended period, although outcomes have demonstrated variability and necessitate a substantial time commitment. Invasive measures encompass surgical interventions or radiation therapy.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: